New Hope or False Dawn? The Reality of Amyloid-Fighting Drugs
Two new drugs, lecanemab and donanemab, have hit the market. They are designed to tackle Alzheimer's disease. They work by targeting and removing beta-amyloid protein from the brain. This protein is a key player in the development of Alzheimer's. The drugs have shown some promising results in clinical trials. They improved scores on cognitive and functional test...